BVF Inc. IL Sells 145,000 Shares of enGene Holdings Inc. (NASDAQ:ENGN)

BVF Inc. IL decreased its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 6.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,106,037 shares of the company's stock after selling 145,000 shares during the period. BVF Inc. IL owned approximately 4.76% of enGene worth $14,005,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vontobel Holding Ltd. purchased a new stake in shares of enGene during the fourth quarter worth about $69,000. Jane Street Group LLC purchased a new position in shares of enGene during the fourth quarter valued at approximately $93,000. Franklin Resources Inc. raised its holdings in shares of enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after acquiring an additional 389,918 shares in the last quarter. Finally, Blue Owl Capital Holdings LP raised its holdings in shares of enGene by 3.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock valued at $21,014,000 after acquiring an additional 101,006 shares in the last quarter. Institutional investors own 64.16% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Piper Sandler started coverage on shares of enGene in a research report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price objective on the stock. JMP Securities reissued a "market outperform" rating and issued a $18.00 price target on shares of enGene in a research note on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of enGene in a research report on Tuesday, March 11th. Morgan Stanley decreased their target price on enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. Finally, UBS Group cut enGene from a "buy" rating to a "neutral" rating and lowered their target price for the company from $34.00 to $7.00 in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $23.29.

enGene Stock Down 13.3 %

enGene stock traded down $0.45 during mid-day trading on Friday, hitting $2.94. The company had a trading volume of 28,589 shares, compared to its average volume of 126,504. The stock's 50 day moving average price is $4.45 and its two-hundred day moving average price is $6.34. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $149.87 million, a PE ratio of -5.07 and a beta of -0.36. enGene Holdings Inc. has a 12 month low of $2.95 and a 12 month high of $14.67.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.